Summary

Temozolomide, an oral alkylating agent, has radiosensitizing properties and has demonstrated promise in previous phase 2 studies involving whole-brain radiation therapy. However, these studies did not include sufficient samples of patients with brain metastases from breast cancer, despite the need for improved treatments for such patients. This article discusses data from a phase 2 prospective randomized multicenter study looking at if the addition of TMZ improves the efficacy of WBRT.